Venus MedTech HangZhou Inc
Venus MedTech HangZhou Inc., a leading innovator in the medical device industry, is headquartered in Hangzhou, China. Founded in 2015, the company has rapidly established itself as a key player in the development of transcatheter heart valve technologies, focusing on minimally invasive solutions for cardiovascular diseases. With a strong emphasis on research and development, Venus MedTech has introduced several core products, including the Venus A-Valve and Venus P-Valve, which are distinguished by their advanced design and patient-centric features. The company has achieved significant milestones, including successful clinical trials and regulatory approvals, positioning itself as a trusted name in the global market. Recognised for its commitment to quality and innovation, Venus MedTech continues to expand its operational reach, contributing to improved patient outcomes in the field of interventional cardiology.
DitchCarbon Score
How does Venus MedTech HangZhou Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Venus MedTech HangZhou Inc's score of 7 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Venus MedTech HangZhou Inc's reported carbon emissions
In 2023, Venus MedTech HangZhou Inc reported total carbon emissions of approximately 410,943 kg CO2e, comprising 88,820 kg CO2e from Scope 1 and 4,020,620 kg CO2e from Scope 2 emissions. The company has also disclosed emissions data for previous years, showing a trend in their carbon footprint. In 2022, their total emissions were about 4,427,710 kg CO2e, with Scope 1 emissions at 70,210 kg CO2e and Scope 2 at 4,357,500 kg CO2e. In 2021, the total emissions reached approximately 5,255,400 kg CO2e, with Scope 1 at 32,620 kg CO2e and Scope 2 at 5,222,780 kg CO2e. The 2020 figures were about 2,365,390 kg CO2e in total emissions, with Scope 1 at 72,370 kg CO2e and Scope 2 at 2,293,020 kg CO2e. The earliest available data from 2019 indicated total emissions of approximately 2,114,960 kg CO2e, with Scope 1 at 26,970 kg CO2e and Scope 2 at 2,087,990 kg CO2e. Despite these figures, Venus MedTech has not set specific reduction targets or climate pledges, indicating a potential area for improvement in their sustainability strategy. The company has disclosed emissions across all relevant scopes (1, 2, and 3), with a significant portion of their emissions stemming from purchased goods and services, particularly in Scope 3, which accounted for 2,114,960 kg CO2e in 2019 and increased to 2,365,390 kg CO2e in 2020. Overall, while Venus MedTech has made strides in tracking their emissions, the absence of formal reduction targets suggests a need for enhanced commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 26,970 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 2,087,990 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,114,960 | 0,000,000 | 0,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Venus MedTech HangZhou Inc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
